Worldwide, there are an estimated one billion archived tissue samples, most of which are formalin-fixed and paraffin-embedded (FFPE) ([@bib4]). Many of these samples are associated with long-term clinical follow-up data. This, coupled with the sequencing of the human genome and the subsequent abundance of molecular biology techniques to support both research and, increasingly, diagnosis, highlights the need to develop approaches for exploiting FFPE archives.

Although tissue and protein are well preserved in FFPE blocks, nucleic acids are degraded and chemically modified ([@bib20]). These deleterious processes, which affect DNA and RNA, occur not only during sample embedding and processing ([@bib38]), but also during long-term storage ([@bib9]). The RNA quality of FFPE samples stored for prolonged periods is known to reduce ([@bib9]), but there is little research on this phenomenon. Given that data quality is an important consideration for bioinformatics analyses, the impact of RNA degradation and chemical modification can be significant, ultimately overwhelming biological variation with noise. Little is known about the factors that determine RNA quality from FFPE tissues. Variables including tissue size, fixation time and storage temperature can negatively affect both RNA quality and the success of PCR assays in controlled laboratory conditions ([@bib38]), but less is known about the processes that occur during prolonged storage. Studies have shown that older FFPE samples have higher *C*~T~ values (i.e., lower signal) than those stored for \<5 years ([@bib9]; [@bib38]). These data suggest that RNA degradation is not a single event, but continues beyond processing and throughout storage. In line with this, most RNA expression studies use FFPE samples \<10 years old ([@bib38]; [@bib1]; [@bib2]), with very few, mostly recent, studies considering older samples ([@bib9]; [@bib12]; [@bib17]). This 10-year limit excludes the majority of FFPE material from analysis. In oncology, this is particularly pertinent for rare cancers, historical studies where shifts in aetiology may be relevant ([@bib6]) and unique sample cohorts ([@bib40]).

Recently, we showed that Exon array profiling and a specialised pipeline that exploits the redundant nature of the arrays can be used to derive a gene signature from FFPE without the requirement for matched fresh-frozen samples ([@bib12]). We consider this to be the cutting edge of FFPE sample expression profiling ([@bib23]) and, unlike earlier techniques, we captured biological information from 100% of samples aged 10--16 years, a higher success rate than other studies ([@bib33]; [@bib24]). We reasoned that Exon array profiling coped with the RNA damage in FFPE samples.

Here, we show that while recent methods cope with RNA degradation in FFPE samples, they are less tolerant of the subsequent mRNA deterioration associated with longer-term storage. To compensate for the long-term deterioration of mRNA signals, we investigated microRNA (miRNA) profiling in older FFPE samples. MicroRNAs are small non-coding sequences of RNA, ∼20--23 nucleotides long, which are involved in the regulation of countless genes. Similar to gene expression, miRNA expression appears to be tightly controlled and provides highly specific biomarkers for cancer ([@bib26]; [@bib19]). MicroRNAs appear to have enhanced stability in both plasma ([@bib31]) and FFPE samples ([@bib22]; [@bib15]). Importantly, we show that miRNAs are not subjected to the same deterioration seen in other RNA types, have robust expression regardless of sample age and can stratify patient samples with negligible mRNA signal.

Materials and methods
=====================

Patients and tissue
-------------------

Samples of histologically proven transitional cell carcinoma of the bladder (stage T~2~, T~3~ or T~4a~) or high-grade non-muscle invasive carcinoma (T~1~ grade 3) from patients participating in the BCON (bladder carbogen nicotinamide) phase III trial ([@bib13]) were selected for Exon array hybridisation (*n*=141). Pre-treatment FFPE biopsies were obtained between November 2000 and April 2006 from 11 UK hospitals; sample processing was carried out according to local standard operating procedures. All tumours contained ⩾10% tumour material. Use of the material was approved by the local ethics committee (LREC 09/H1013/24).

Samples of histologically proven carcinoma of the cervix (FIGO stage I~b~--IV~a~) from patients treated with radiotherapy alone with curative intent were selected for Exon array hybridisation (*n*=160). Pre-treatment FFPE biopsies were obtained between 1987 and 2002 from the Christie Hospital. The samples were collected and processed at a single hospital site, using the same standard operating procedure over the period they were obtained, that is, the same methods of fixation and embedding used today, although changes in the quality and composition of reagents cannot be excluded. Tumour biopsies were obtained under general anaesthetic and immersed in 4% neutral-buffered formalin. The FFPE blocks were stored at room temperature in a standard block storage unit. Unfortunately in the clinical setting other features associated with fixation were not recorded (e.g., duration of fixation, tumour volume, etc.); however, all samples were processed routinely and therefore are representative of the types of cohort available for FFPE research. All tumours contained ⩾30% tumour material. Local ethical approval was obtained for using the human material (LREC: 08/H1011/63).

RNA extraction and quality control (QC)
---------------------------------------

RNA was extracted and DNase treated using RecoverAll Total Nucleic Acid Isolation Kit (Ambion, Austin, TX, USA), as per manufacturer\'s instructions. We have previously shown that this kit was sufficiently optimised for sarcoma FFPE samples without the need for additional modification ([@bib23]). RNA integrity and RNA quantification were measured using a Bioanalyser (Agilent Technologies Ltd, Santa Clara, CA, USA). Ratios of 260/230 and 260/280 were assessed using a Nanodrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Nanodrop-quantified cDNA yield was also recorded. Minimum requirements for hybridisation to Exon arrays were an input of 100 ng total RNA that amplifies to give a yield of ⩾3.8 *μ*g of cDNA. In two cervix carcinoma cases (V153 and V247), 50 ng of RNA was used as input, owing to a low RNA yield. As such, 100% of cases had usable amounts of RNA. Samples that were dilute (\<50 ng *μ*l^−1^) were concentrated under vacuum (Eppendorf concentrator 5301; Eppendorf, Hamburg, Germany). The standard RNA quality parameters: RIN (a measure of the proportion of intact ribosomal RNA (rRNA)), 260/230 ratio and 260/280 ratio were recorded, but not used to screen samples. Full RNA QC data were available for 89% (125/141) of bladder and 87% (139/160) of cervix cancer samples hybridised to Exon arrays. The remaining samples had one or more parameters where data were not recorded.

Exon array hybridisation
------------------------

One hundred nanograms of RNA was amplified using NuGen WT-Ovation FFPE v2 kit (NuGen Technologies, San Carlos, CA, USA). The WT-Ovation Exon Module V1.0 was used to generate ST-cDNA, and 3.8--4 *μ*g was hybridised to Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA). Further details and raw data (CEL files) are available at <http://bioinformatics.picr.man.ac.uk/vice> (or GSE39067).

Exon array data analysis
------------------------

Microarray data were normalised using RMA ([@bib16]). R/BioConductor package annmap and annmap database ([@bib41]) were used to filter non-exonic and multitargeting probesets. Array performance was measured as the percentage of probesets flagged as 'present\' with a conservative cutoff (%detection above background (%DABG) *P*\<0.01) and only those probesets 'present\' in at least three samples were analysed. Gene level summaries were calculated by taking the median signal of filtered probesets that mapped to unique gene symbols. Affymetrix Exon 1.0ST array hybridisation reproducibility was assessed using standard Affymetrix Exon array QC measures ([Supplementary Text](#sup1){ref-type="supplementary-material"} and [Supplementary Figures 1--3](#sup1){ref-type="supplementary-material"}). Samples with more than two QC measures ±10% of the cohort mean were considered outliers. Principle component analysis was also used to assess sample variation within cohorts. [Supplementary Figures 1--3](#sup1){ref-type="supplementary-material"} show that no samples failed this QC check and so none were excluded from the analysis. An adenocarcinoma/squamous cell carcinoma (AC/SCC) ratio was derived by using a previously published signature comprising 2673 probesets ([@bib12]). The median expression values of 2395 SCC probesets were divided by that of 278 AC probesets. Scores \>1 were classified as SCC and scores \<1 as AC. The same ratio was calculated for 100 sets of 2673 randomly sampled probesets for comparison.

TaqMan miRNA qRT--PCR
---------------------

Ten nanograms of RNA was reverse transcribed using the TaqMan MicroRNA Reverse Transcription (RT) Kit (Applied Biosystems, Carlsbad, CA, USA) and pooled Taqman RT primers for hsa-miR-205 (000509), hsa-miR-26b (000407) and hsa-miR-16 (000391). Complementary DNA was amplified using the TaqMan PreAmp Master Mix, as per the manufacturer\'s protocol, for 14 cycles (Applied Biosystems). Five microlitres of amplified cDNA was subjected to quantitative PCR using the same TaqMan primers and probes used in the RT stage. Standard Gene Expression Mastermix (Applied Biosystems) and thermocycling conditions were utilised, data were collected using an AB7900 and values exported from SDS2.1 for analysis in Excel. Relative quantification was performed using the 2^−ΔCT^ method ([@bib25]), including normalisation of the target expression data (hsa-miR-205) to the mean of housekeeping miRNA expression (hsa-miR-26b and hsa-miR-16) ([@bib32]).

MicroRNA array hybridisation
----------------------------

One hundred nanograms of total RNA was tailed and ligated to FlashTag-Bitoin-HSR as per the manufacturer\'s protocol (Affymetrix). The ligated RNA was then hybridised to Affymetrix miRNA v2.0 arrays for 16 h at 48 °C. Further details and raw data (CEL files) are available at <http://bioinformatics.picr.man.ac.uk/vice> or GSE39067. Raw data were analysed using the Affymetrix 'miRNA QC tool\' (v1.1.1.0), using standard parameters including quantile normalisation. The Affymetrix miRNA v2.0 array contains probesets for multiple species, and different small-non-coding RNA molecules such as stem loops (pre-miRNA precursors), and small nucleolar RNA (snoRNA) and small Cajal body-specific RNA (scaRNAs). Probesets were filtered to retain only those annotated for *Homo sapiens* and miRNA (mature, processed). SnoRNA (including CDBox and HAcaBox) were also considered, but independently to mature miRNAs. Pre-miRNA data from the miRNA v2.0 array were not considered owing to consistently low expression in FFPE and cell line RNA ([Supplementary Figure 4A and B](#sup1){ref-type="supplementary-material"}). Therefore, pre-miRNA data for miR205 were derived from the Exon array. Differential expression analysis of filtered probesets was performed using LIMMA ([@bib36]).

Cell lines and western data
---------------------------

Cervix cell lines were grown in DMEM+10% foetal calf serum. Western blotting was performed using the following antibodies: p63 mouse monoclonal (BC4A4) (Abcam, Cambridge, UK) and alpha-tubulin mouse monoclonal (020M4753) (Sigma-Aldrich, Dorset, UK). Protein expression rather than pathological assignment was used to broadly classify lines as SCC (p63+) and AC (p63−).

p63 immunohistochemistry
------------------------

Sections (4 *μ*m) were dewaxed, rehydrated and the antigen retrieved by microwaving in Low pH Antigen Unmasking Solution (Vector Laboratories Inc., Peterborough, UK). After quenching endogenous peroxidase, nonspecific binding was blocked using 10% casein (Vector Laboratories Inc.). The primary antibody, mouse monoclonal (BC4A4) (Abcam), was applied at 10 *μ*g ml^−1^, and the sections incubated at 4 °C in a humidified chamber overnight. The same concentration of mouse IgG2a control reagent (Dako Ltd, Ely, UK) was used as negative control. The antigen was detected with mouse EnVision Plus reagent (Dako Ltd) and visualised with 3,3′-diaminobenzidine (Dako Ltd). Sections were counterstained with haematoxylin, dehydrated and mounted. Batch-to-batch variation was assessed by running sections showing high and low p63 expression with each batch. Tumours exhibiting ⩾5% positive nuclei were classed as p63 positive ([@bib7]). Immunohistochemistry methods followed REMARK guidelines ([@bib30]).

Statistics
----------

*R* values indicate Pearson product moment correlation coefficient. Asterisks indicate *P*-value thresholds \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001. Box-whisker parameters: horizontal bar indicates median expression, the box indicates interquartile range; whiskers represent the range. LIMMA ([@bib36]) was used to calculate differential expression values for miRNA profiling data. *P*-values are Benjamini and Hochberg false-discovery rate (FDR) corrected ([@bib3]).

Results
=======

RNA quality affects the technical success of Exon array profiling
-----------------------------------------------------------------

Optimisation of RNA extraction from FFPE is an important consideration and should take into account length of fixation and duration of sample storage ([@bib35]; [@bib8]). To ensure that the RNA extraction protocol was optimised for our older cervix samples, we performed a pilot experiment on four samples stored 2--14 years (cohort median age: 13.9 years). Good yields (3--19 *μ*g per 60 *μ*m tissue) were obtained using the standard RecoverAll protocol and %DABG scores similar to cell line RNA (data not shown). Following the pilot experiments, remaining samples were hybridised. Complete RNA QC data were available for 125 bladder and 139 cervix samples. [Figure 1A](#fig1){ref-type="fig"} shows that neither RNA yield nor RIN correlated with %DABG, which measures array performance ([@bib24]; [@bib37]). The average RIN of both the bladder and cervix samples was ∼2.3 ([Figure 1B](#fig1){ref-type="fig"}), showing considerable rRNA degradation compared with cell line RNA ([Figure 1C](#fig1){ref-type="fig"}). The data show that rRNA integrity is a poor predictor of successful archival FFPE array profiling. The standard spectrophotometric determinants of RNA purity (260/230 and 260/280 ratio) also failed to correlate with %DABG ([Figure 1A](#fig1){ref-type="fig"}). Complementary DNA yield following NuGEN amplification correlated weakly with %DABG in both the bladder (*R*=0.19) and cervix (*R*=0.39) cohorts (*P*\<0.05 for both). Of note, yield might be a better predictor than suggested by these data, as samples yielding \<3.8 *μ*g cDNA cannot be hybridised to arrays. However, cDNA yield accounts for only a small amount of sample variation.

FFPE sample age is the predominant feature associated with poor array performance
---------------------------------------------------------------------------------

The range of %DABG values was lower in the bladder (median 24.0% (range 12.6--34.0%)) than the cervix (median 19.2%, (range 4.4--40.9%)) samples. It is possible that tissue type contributes to the difference, but the bladder samples were younger (median age 6 years (6--8)) than the cervix cohort (median age 13 years (8--23)). Therefore, we examined whether FFPE block age at RNA extraction contributed to array performance. There was a statistically significant trend for %DABG to decrease with sample age in both the bladder (*R*=−0.30, *P*\<0.01; [Figure 1D](#fig1){ref-type="fig"}) and cervix (*R*=−0.69, *P*\<0.01; [Figure 1E](#fig1){ref-type="fig"}) series. This clearly demonstrates in two independent cohorts that the older an FFPE sample the poorer the array performance. The effect size was almost negligible in the younger bladder cancer cohort, but coupled with the cervix data it suggests that over time the %DABG might similarly decay. Neither RNA yield nor RIN correlated with the age of FFPE block ([Supplementary Figures 5 and 6](#sup1){ref-type="supplementary-material"}).

Biological signal is lost in older samples
------------------------------------------

%DABG measures technical success, but does not reflect 'biological signal\' success. To address this, we investigated whether a gene signature discriminated AC and SCC in older FFPE samples. To remove any tissue of origin concerns we focused on the cervix samples, which had the broadest age range. The cervix samples were divided into two series based on historical enrolment into two different studies. Cervix series 1 (CS1) comprised 112 FFPE samples with a median age of 12 years (range 8--18), and cervix series 2 (CS2) contained 48 FFPE samples with a median age of 18 years (range 16--23) ([Table 1](#tbl1){ref-type="table"}). We have previously published a gene signature that is capable of separating cervix into AC and SCC histology, based on the expression of 1062 SCC and 155 AC genes ([@bib12]). This signature was derived on 28 cervix FFPE samples, but most importantly shown to independently validate in a fresh-frozen, lung cancer cohort. Expressing the signature as a ratio (dividing the expression of the 1062 SCC genes by the expression of 155 AC genes) results in a positive ratio indicating a higher contribution from SCC genes. [Figure 2A and B](#fig2){ref-type="fig"} shows clear discrimination of SCC and AC samples in the original cervix training data and lung cancer validation cohort ([@bib12]). The ratio in the AC samples was higher in the lung than cervix, possibly owing to differences in gene expression between the cancer types. [Figure 2C](#fig2){ref-type="fig"} shows the age range of the two cervix cohorts and [Figure 2D](#fig2){ref-type="fig"} the obvious biological signal in CS1 specimens with only a minority of SCC samples having ratios close to or below background. As with most classifiers, there are some histological misclassifications, but most of the younger samples were correctly classified as SCC. In contrast, the older SCC samples show a clear reduction in performance with most of the SCC samples having ratios close to or below background ([Figure 2E](#fig2){ref-type="fig"}). None of the FFPE samples had a ratio above 1.2, even though ∼90% of cervix cancers are SCC. Taken together, these data demonstrate that the older FFPE samples have lost biological signal. We also saw a weak trend for decreasing housekeeper expression with sample age in our data; however, there was considerable sample variation ([Supplementary Figures 7 and 8](#sup1){ref-type="supplementary-material"}). Interestingly, there was no significant difference in housekeeping gene expression or distribution associated with %DABG filtering or between the older and newer samples.

mRNA transcript expression is progressively lost during long-term FFPE storage
------------------------------------------------------------------------------

Biological signal progressively decreased during storage as shown by the correlation between SCC/AC ratio and sample age (*R*=0.76, [Figure 3A](#fig3){ref-type="fig"}). Furthermore, the strong correlation between SCC/AC ratio and %DABG ([Figure 3B](#fig3){ref-type="fig"}) demonstrates that this is a general feature of the data: FFPE sample storage is associated with a progressive drop in RNA quality, resulting in a general decline in the 'biological\' signal to noise ratio. This is further demonstrated by the decrease in probeset signal for TP63, which encodes the tumour suppressor p63, a protein expressed predominantly in cells and tumours of squamous cell origin. Expression of the p63 protein, measured by immunohistochemistry, is currently considered to be the best single biomarker of cervical SCC ([@bib29]). Like the SCC/AC ratio, Exon array-measured TP63 transcript abundance decreased with cervix sample age (*R*=−0.63, [Figure 3C](#fig3){ref-type="fig"}). As a positive control for RNA quality, and to confirm the relationship between p63 protein and transcript expression, p63 levels were measured in 16 cervix cancer cell lines by western blot ([Figure 3D](#fig3){ref-type="fig"}). The median gene expression level for TP63 was higher in p63-positive *vs* p63-negative cell lines ([Figure 3E](#fig3){ref-type="fig"}). While the background level of TP63 signal was relatively constant (green boxes) across cell lines and tumour cohorts, there is a decrease in the TP63 signal for SCC that is proportionate to RNA quality (hatched boxes). In the older cervix series this eliminated the difference between AC and SCC. These results are further supported by immunohistochemistry data for 152 samples, where median TP63 expression in the older samples was closer to background (p63 negative) levels ([Figure 3F](#fig3){ref-type="fig"}). As these data represent the median values for multiple probesets targeting the length of the gene, it is probable that the RNA degrades along the entire length of the TP63 transcript.

Mature miRNA expression can overcome mRNA degradation and accurately classify cervix tumours
--------------------------------------------------------------------------------------------

MicroRNAs were explored for their ability to overcome the limitations of mRNA profiling. The miRNA miR-205 has previously been demonstrated as a marker of lung SCC ([@bib19]). Two Exon array probesets target the full-length hsa-mir-205 (mir-205) precursor. Both probesets correlate with TP63 expression ([Figure 4A](#fig4){ref-type="fig"}) in our previously published cohort ([@bib12]). We interrogated whether expression of these probesets correctly classified samples according to histology. The expression of both mir-205 probesets was similar to TP63 ([Figure 4B](#fig4){ref-type="fig"}). While the probeset expression in SCC samples (hatched boxes) was higher in the cell lines and younger FFPE samples (*P*\<0.01), there was no statistically significant difference between SCC and AC in the older samples. MicroRNA probesets on Exon arrays target precursor miRNAs (pre-miRNA) sequences, which are longer, in this case 110 nt, than the mature processed miRNAs (∼22 nt). The implication is that pre-miRNAs are subject to similar degradation effects as mRNAs. To address this, a subset of samples was randomly selected from the cervix cohort, to encompass all ages and RNA qualities ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). A qRT--PCR assay was designed to specifically detect the mature form of miR-205 and performed on the same RNA used to generate the array data. Both mir-205 probesets, and the median expression of TP63, failed to discriminate between AC and SCC in the older FFPE cohort ([Figure 4C](#fig4){ref-type="fig"}). However, signal for the mature miR-205 was significantly higher in SCC compared with AC across all RNA qualities ([Figure 4D](#fig4){ref-type="fig"}). There was no significant age-related decay in signal between the CS1 and CS2 subsets. The CS1 samples showed a 7.6-fold difference in expression of miR-205 between AC and SCC, and the CS2 subset showed a 6.9-fold difference ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}). This confirms that mature miR-205 expression discriminates between AC and SCC in RNA with no discernable mRNA signal.

Global miRNA profiling confirms that miRNAs have enhanced stability in FFPE samples
-----------------------------------------------------------------------------------

To test whether this result generalised to global miRNA profiling, 16 FFPE samples and 2 cell lines were hybridised to Affymetrix miRNA v2.0 arrays. Clinical samples were randomly selected from either cohort of cervix samples. [Figure 5A](#fig5){ref-type="fig"} shows the probeset expression of hsa-miR-205 derived from the array data. There is clear separation of SCC and AC in the cervix samples, recapitulating the qRT--PCR data ([Figure 4D](#fig4){ref-type="fig"}). Taken together, these data show that miR-205 expression levels support histological discrimination, regardless of sample age or quality, even in FFPE samples where mRNA expression cannot. [Figure 5B](#fig5){ref-type="fig"} shows that the median probeset expression of all human miRNAs for eight young cervix samples correlates well with the probeset expression of eight old cervix samples (*R*=0.95) with no apparent age-related bias. An equivalent plot for a random sampling of a similar sized subset of (*n*=1000) mRNA (Exon) probesets was skewed towards the higher signal in younger (CS1) samples (*R*=0.88) ([Figure 5C](#fig5){ref-type="fig"}). This shift is more pronounced for the 2395 probesets comprising the SCC component of the AC/SCC signature (*R*=0.72). Together, these data suggest the miRNA data are more robust to the effects of FFPE processing and storage. We therefore compared miRNA profiles for SCC *vs* AC samples, irrespective of sample age ([Figure 5D](#fig5){ref-type="fig"}). While a number of probesets showed differential expression ([Figure 5E](#fig5){ref-type="fig"}), only miR-205 (26-fold higher in SCC compared with AC) was statistically significant after FDR adjustment (*P*=1.103 × 10^--5^). This supports previous reports in the literature that miR-205 is a suitable biomarker for SCC, and for the first time we demonstrate its ability to discriminate cervix cancer histologies. Another small-non-coding class of RNA molecule represented on the Affymetrix miRNA v2.0 array, snoRNAs, shows stability across the two sample cohorts (*R*=0.97, *P*\<0.0001) ([Figure 5F](#fig5){ref-type="fig"}). [Figure 5F](#fig5){ref-type="fig"} shows that this correlation is preserved in probesets detecting the entire range of target molecule sizes.

Discussion
==========

Specimen size, time to fixation and fixation duration affect the quality of RNA from FFPE archival samples ([@bib38]). There is also a progressive deterioration of RNA quality associated with long-term storage. The lack of standardisation in tissue processing and storage in histopathology departments means that it is not possible to access samples handled uniformly. Given the vast archives of FFPE tumour material available, techniques are required that cope with a high degree of sample variation owing to processing and degradation. Approaches are also needed that predict whether samples can be successfully profiled with RNA expression techniques. This study investigated whether an approach that worked with samples stored for 10--16 years ([@bib12]) could cope with the systematic degradation of RNA in even older FFPE samples ([@bib9]). We envisaged that the short 25mer probes on the Exon arrays would deal with RNA fragmentation better than qRT--PCR and consequently we performed no pre-selection based on standard RNA quality metrics, or PCR expression of endogenous controls ([@bib35]; [@bib34]; [@bib39]).

Standard RNA QC parameters did not predict microarray profiling success and there was only a very weak correlation for decreasing reference gene expression in older samples. The level of rRNA degradation, as measured by RIN, was not a predictor of FFPE microarray profiling success. The lack of correlation between RIN and %DABG agrees with previous studies demonstrating that 1-year-old FFPE expression, as measured by qRT--PCR, is comparable to that of fresh-frozen material, providing small amplicons are used ([@bib9]; [@bib38]). This is further supported by a recent study of QC parameters in unfixed postmortem brain specimens, in which only 2.7% of the variation in array performance in a 1266 Exon array experiment could be accounted for by RIN (range 1--8.5) ([@bib37]). This suggests that the RNA deterioration that contributes to poor RIN can be overcome by the combined use of RNA amplification, that is not solely reliant on poly(A)-based priming, and multiple short reporters, such as the probesets found on Exon arrays.

In both the bladder and cervix cancer FFPE samples, a statistically significant association was seen between decreasing array performance (%DABG) and sample age, suggesting that during prolonged storage the RNA becomes increasingly incompatible with current methods. In the cervix cohort, we showed that samples with low %DABG also had low biological signal and it was not possible to distinguish between AC and SCC (AC/SCC ratio or TP63 transcript). As FFPE samples age, both total RNA quality and signal (%DABG) decreased and biological signal was lost. This finding supports the recommendation that FFPE samples should have RNA extracted as soon as possible after fixation, preferably within 1 year ([@bib38]). With prospective translational studies or clinical tests this is sometimes achievable, but adhering to this recommendation would clearly remove many potentially valuable retrospective FFPE samples from further analysis. Our study is the first to show these trends in global mRNA profiles. Given that we have quantitatively validated Exon array FFPE data previously ([@bib12]), the loss of biological signal in samples stored for 16--23 years should recapitulate with other methods for measuring RNA expression such as qRT--PCR or Quantigene. Other approaches were not explored owing to limited material available but loss of expression with age has been reported previously using qRT--PCR ([@bib9]). Our findings, therefore, are likely to generalise to other FFPE profiling methods given the similarity of approach (e.g., array designs featuring 3′ reporters). While adjustments to data analysis and normalisation methods, such as normalising to invariant probesets/housekeeping genes ([@bib9]; [@bib17]), might help correct for age-related effects, it is unreasonable to expect them to be able to reconstruct information that is missing in the original data. Formalin-fixed paraffin-embedded cohorts will inherently contain significant amounts of technical and biological variation, leading to the need for larger cohorts than an equivalent study using fresh-frozen material. There are currently no prospective QC metrics that can universally predict array performance. In this study, the strongest indicator of array success was sample age, therefore younger aged cohorts should be exploited where possible.

There is increasing evidence in the literature that miRNAs show enhanced stability in both plasma ([@bib31]) and FFPE ([@bib22]; [@bib15]). The miR-205 was investigated as a biomarker of SCC ([@bib19]). The precursor transcript behaved in a similar way to mRNA and also failed to discriminate between AC and SCC in older samples. However, mature miR-205 was able to distinguish cervical samples by histological subtype. It was considered that this might be owing to the high expression of miR-205 (i.e., higher levels of transcript to degrade, compared with mRNA markers). As expected in the mRNA data, there was a significant decrease in signal in the older samples compared with the newer FFPE samples. This decrease was not observed when comparing the expression of human mature miRNAs (*n*=1105) suggesting that the enhanced stability associated with miR-205 is a general feature of all detected miRNAs. Given the diverse roles of miRNAs and their enhanced stability independent of expression level, there is great potential for miRNA profiling to contribute to the development of clinical biomarkers ([@bib26]; [@bib19]) and the generation of signatures associated with outcome ([@bib14]; [@bib10]) especially using FFPE samples.

There are multiple hypotheses concerning why miRNA is more stable than mRNA in FFPE. First, either the lack of structure, lack of a specific nucleotide target sequence, their small size or some other protective modification prevents the degradation that occurs with larger RNA molecules. Second, the miRNAs are in a protective environment such as the RNA-induced silencing complex, that by the virtue of formalin crosslinks are tethered to the miRNA or alternatively, because they are packaged into vesicles known as exosomes ([@bib21]). It may also be that miRNAs provide a better template for amplification or have hybridisation kinetics that are less affected by the processes occurring in FFPE. It is interesting therefore that snoRNAs, a different class of small-non-coding RNA, with their significantly larger size (48--250 nt) and different subcellular location also demonstrate enhanced stability in FFPE. SnoRNAs primarily guide chemical modifications of other RNA molecules ([@bib28]). SnoRNAs have been associated with genetic conditions such as Prader--Willi syndrome ([@bib5]) and dyskeratosis congenita ([@bib27]). It is becoming clear that snoRNAs also regulate other biological processes such as alternative splicing ([@bib18]) and even function as non-classical miRNAs ([@bib11]). Understanding the commonalities between snoRNAs and miRNAs will provide further insight into why some RNA molecules degrade less than others when formalin-fixed and paraffin-embedded.

Other studies have reported improvements in expression profiling by using miRNAs in conjunction with FFPE. This is, however, to the best of our knowledge the first study to show that archival FFPE RNA, that is severely degraded and empirically incompatible with mRNA expression methods, can yield meaningful biology when combined with miRNA expression profiling. Our study therefore provides strong support for the use of miRNA profiling in archival FFPE samples especially when an investigation requires the analysis of older, more recalcitrant material.
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![RNA quality affects the technical success of Affymetrix Exon arrays. (**A**) Table displaying the correlation coefficients (*R*) between RNA quantification and QCs against %DABG; RIN number, 260/230 ratio, 260/280 ratio and concentration. Complementary DNA yield following NuGen amplification was also considered as a surrogate for RNA quality. Emboldened values show significant *P*-values: \**P*\<0.05, \*\**P*\<0.01. (**B**) Table displaying the median RNA quantification and QC values for the bladder cancer cohort (*n*=125) and the combined cervix cancer cohort (*n*=139). Brackets indicate range. (**C**) Bioanalyser traces showing intact cell line RNA (MCF10A) with an RIN number of 10 and a representative cervix FFPE sample (V554) with a RIN of 2.10. Fragment size is on *x* axis (migration time in seconds), with abundance (fluorescent units) shown on the *y* axis. Formalin-fixed paraffin-embedded samples show loss of the 18S and 28S ribosomal subunit peaks seen in the cell line RNA. (**D**) *x*--*y* scatterplot showing %DABG against age of FFPE block (in years) for the bladder cancer cohort. The plotted line represents a line of best fit. (**E**) *x*--y scatterplot showing %DABG against age of FFPE block (in years) for the cervix cancer cohort. The plotted line represents a line of best fit.](bjc2012294f1){#fig1}

![Application of a signature capable of discriminating AC from SCC to the cervix cancer cohort. The ratio of the median expression of 1062 genes associated with SCC divided by the median expression of 155 genes associated with AC ([@bib12]) is plotted per sample (black circles). Five hundred bootstraps of a random selection of genes of the same size are also plotted (grey circles). The bar indicates sample histology. Squamous cell carcinoma samples are indicated by the vertical lines, AC by the spotted grey bar and samples with pathologically undefined/unclear histology are represented by horizontal bars. (**A**) Applied to the original (training) cohort (*n*=28) of AC/SCC samples ([@bib12]). Samples in this FFPE cohort have a median age of 11 years (10--16) (**B**) Applied to the independent non-small-cell lung cancer (NSCLC) cohort ([@bib12]). The samples in this cohort were fresh-frozen. (**C**) Partitioning of the samples into two independent cohorts on the basis of historical partitioning. Cervix series 1 (squares) indicate the younger cervix series one (median age 12 years (8--18)) and CS2 (stars) indicate cervix series two (median age 18 years (16--23)). (**D**) AC/SCC signature applied to the CS1 cohort (of similar age to the original training samples). (**E**) AC/SCC signature applied to CS2, an older independent cohort of cervix cancer samples.](bjc2012294f2){#fig2}

![The age of the FFPE block is associated with loss of biological signal. (**A**) *x*--*y* scatterplot showing the ratio of SCC/AC gene signature (*y* axis) against the age of FFPE block in years (*x* axis). Pearson correlation coefficient (*R*) is displayed. (**B**) *x*--*y* scatterplot showing the ratio of SCC/AC gene expression (*y* axis) against %DABG (*x* axis). Pearson correlation coefficient (*R*) is displayed. (**C**) *x*--*y* scatterplot showing median TP63 expression plotted against the age of the FFPE block. Pearson correlation coefficient (*R*) is displayed. (**D**) Western blot of p63 protein expression in 16 cervix cancer cell lines. (**E**) Box-whisker plot showing Exon array probeset expression of TP63 in AC and SCC from three cohorts; cervix cell lines (*n*=16), CS1; intermediate age FFPE (*n*=112) and CS2; old FFPE *n*=48. (**F**) Box-whisker plot for a subset of FFPE samples where sufficient tissue was available for p63 immunohistochemistry (CS1 *n*=108, CS2 *n*=44). *y* axis shows the median TP63 probeset expression from Exon array data. *x* axis shows p63 immunohistochemistry status; positive (\>5% nuclei) or negative (\<5% nuclei) for samples within the younger CS1 and older CS2 cohorts.](bjc2012294f3){#fig3}

![Expression of miRNA hsa-miR-205 can discriminate between AC and SCC in poor-quality samples. (**A**) Graph showing the median probeset expression of TP63 and two probesets representing hsa-mir-205 in the original training set for the AC/SCC signature ([@bib12]). Vertical bars indicate SCC samples. Hatched line indicates the split between SCC and AC samples (**B**) Box-whisker plot showing expression of two probesets (2377992) and (2377993) representing hsa-mir-205 expression across the three series; cell lines, CS1 and CS2 FFPE cohorts. *T*-test *P*-values are shown as: \*\**P*\<0.01. \*\*\**P*\<0.001. n.s., not significant (**C**) Graph showing the expression of TP63, hsa-mir-205 (2377992) and hsa-mir-205 (2377993) from the Exon array data across a subset of samples randomly selected from the three series; cell lines, intermediate age FFPE (CS1), old FFPE (CS2). Each value represents an individual sample and the horizontal bar displays the median. (**D**) Taqman qRT--PCR data showing the relative expression of hsa-miR-205 normalised to hsa-miR-16.1 and hsa-miR-26b expression across the random subsets from the three series; cell lines, CS1 and CS2 FFPE samples. Each value represents an individual sample and the bar displays the median.](bjc2012294f4){#fig4}

![Global microRNAome profiling confirms that microRNAs have enhanced stability in FFPE samples. (**A**) Affymetrix miRNA 2.0 array data for probeset hsa_miR-205_st. Each point represents an independent sample and the horizontal bar indicates the median. Eight samples were hybridised from the younger CS1 cohort (four AC and four SCC) and eight samples were hybridised from the older CS2 cohort (four AC and four SCC) along with a single example of SCC and AC cell line RNA. (**B**) *x*--*y* scatterplot showing the miRNA (miRNA 2.0 array) median probeset expression values for all 1105 miRNA probes. *y*-axis values are the median of eight CS1 samples and *x*-axis values are the median of eight CS2 samples. Pearson correlation coefficient (*R*) is displayed. (**C**) *x*--*y* scatterplot showing the mRNA (Exon array)-derived median probeset expression for 1000 randomly selected probesets (grey) and 2395 SCC-specific probesets derived from the AC/SCC signature (hollowed circles). *y*-axis values are the median of eight CS1 samples and *x*-axis values are the median of eight CS2 samples. Pearson correlation coefficient (*R*) is displayed. (**D**) Volcano plot showing the results of LIMMA differential expression analysis between eight SCC and eight AC samples. *x* axis represents fold change (log2) and the *y* axis details LIMMA odds ratio, a measure of statistical change. Probesets with positive or negative fold change less than twofold (log~2~=1) are coloured grey. Probesets with a fold change greater than twofold are coloured black. Star-shaped data points represent statistically significant probesets with an FDR-adjusted *P*-value \<0.05. (**E**) Table listing differentially expressed probesets with a log~2~ fold change ⩾1.5 fold. (**F**) *x*--*y* scatterplot showing the snoRNA median probeset, expression values for all 510 snoRNA, CDbox and HAcaBox probes (miRNA 2.0 array). *y*-axis values are the median of eight CS1 samples and *x*-axis values are the median of eight CS2 samples. Gradient colouring is based on the size of the target molecule, between 48 nt (blue) and 250 nt (red). Pearson correlation coefficient (*R*) is displayed.](bjc2012294f5){#fig5}

###### FFPE cohort information

            **Cohort**              **Tumour type**   **Number of patients**   **Median age of sample (years)**   **Median %DABG**
  --------- ----------------------- ----------------- ------------------------ ---------------------------------- -------------------
  Bladder   ---                     Bladder cancer    141                      6 (3--8)                           24.0 (12.6--34.5)
                                                                                                                   
  Cervix    Cervix series 1 (CS1)   Cervix cancer     112                      12 (8--18)                         22.6 (8.3--40.9)
                                                                                                                   
            Cervix series 2 (CS2)   Cervix cancer     48                       18 (16--23)                        13.9 (4.4--27.6)
                                                                                                                   
            Combined series         Cervix cancer     160                      13 (8--23)                         19.2 (4.4--40.9)

Abbreviation: %DABG=percentage detection above background.

Numbers in brackets represent the range.

[^1]: These authors contributed equally to this work.
